Trial Profile
A double-blind, randomised, placebo-controlled, parallel-group, multicentre, phase III study to assess the impact of rosuvastatin treatment for 26 weeks (titrated to a maximum dose of 40mg once daily) on left ventricular function, cytokines and lipid parameters in patients with established systolic chronic heart failure.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Rosuvastatin (Primary)
- Indications Chronic heart failure
- Focus Pharmacodynamics
- Sponsors AstraZeneca
- 10 Sep 2008 New trial record.